Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor
- PMID: 31042258
- PMCID: PMC6495363
- DOI: 10.1001/jamadermatol.2019.0440
Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor
Abstract
Importance: With emerging new systemic treatments for metastatic melanoma, early detection of disease recurrence is increasingly important.
Objective: To investigate the risk of melanoma recurrence in patients with a localized melanoma at a high risk of metastasis.
Design, setting, and participants: A total of 1254 patients with newly diagnosed, histologically confirmed tumor category T1b to T4b melanoma in Queensland, Australia, were recruited prospectively between October 1, 2010, and October 1, 2014, for participation in a cohort study. Data analysis was conducted from February 8, 2018, to February 20, 2019. We used Cox proportional hazards regression analysis to examine associations between patient and tumor factors and melanoma recurrence.
Exposures: Disease-free survival (DFS) by melanoma tumor category defined by the 7th vs 8th editions of the AJCC Cancer Staging Manual (AJCC 7 vs AJCC 8).
Main outcomes and measures: Melanoma recurrences were self-reported through follow-up questionnaires administered every 6 months and confirmed by histologic or imaging findings.
Results: Of 1254 patients recruited, 825 individuals (65.8%) agreed to participate. Thirty-six were found to be ineligible after providing consent and a further 89 patients were excluded after reclassifying tumors using AJCC 8, leaving 700 participants with high-risk primary melanoma (mean [SD] age, 62.2 [13.5] years; 410 [58.6%] men). Independent predictors of recurrence were head or neck site of primary tumor, ulceration, thickness, and mitotic rate greater than 3/mm2 (hazard ratio, 2.36; 95% CI, 1.19-4.71). Ninety-four patients (13.4%) developed a recurrence within 2 years of diagnosis: 66 tumors (70.2%) were locoregional, and 28 tumors (29.8%) developed at distant sites. After surgery for locoregional disease, 37 of 64 patients (57.8%) remained disease free at 2 years, 7 patients (10.9%) developed new locoregional recurrence, and 20 patients (31.3%), developed distant disease. Two-year DFS was similar when comparing AJCC 7 and AJCC 8, for T1b (AJCC 7, 253 [93.3% DFS]; AJCC 8, 242 [93.0% DFS]) and T4b (AJCC 7 and AJCC 8, 50 [68.0% DFS] category tumors in both editions. Patients with T2a to T4a tumors who did not have a sentinel lymph node biopsy (SLNB) at diagnosis had lower DFS than patients with the same tumor category and a negative SLNB (T2a: 136 [91.1%; 95% CI, 86.4-95.9] vs 96 [96.9%; 95 % CI, 93.4-100.0]; T4a: 33 [78.8%; 95% CI, 64.8-92.7] vs 6 [83.3; 95% CI, 53.5-100.0]).
Conclusions and relevance: These findings suggest that 13.4% of patients with a high-risk primary melanoma will experience disease recurrence within 2 years. Head or neck location of initial tumor, SLNB positivity, and signs of rapid tumor growth may be associated with primary melanoma recurrence.
Conflict of interest statement
Figures
Comment in
-
The Changing Kinetics of Advanced Melanoma.JAMA Dermatol. 2019 Jun 1;155(6):657-659. doi: 10.1001/jamadermatol.2019.0200. JAMA Dermatol. 2019. PMID: 31042261 No abstract available.
Similar articles
-
Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.Am J Surg Pathol. 2019 Dec;43(12):1701-1710. doi: 10.1097/PAS.0000000000001344. Am J Surg Pathol. 2019. PMID: 31425167
-
Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.JAMA Dermatol. 2019 May 1;155(5):572-577. doi: 10.1001/jamadermatol.2018.5902. JAMA Dermatol. 2019. PMID: 30840034 Free PMC article.
-
Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system.JAMA Dermatol. 2014 Jan;150(1):19-24. doi: 10.1001/jamadermatol.2013.6675. JAMA Dermatol. 2014. PMID: 24226651 Review.
-
Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22. Eur J Cancer. 2009. PMID: 19553103
-
[Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].J Dtsch Dermatol Ges. 2005 Aug;3(8):592-8. doi: 10.1111/j.1610-0387.2005.05051.x. J Dtsch Dermatol Ges. 2005. PMID: 16033477 Review. German.
Cited by
-
Temporal Recurrence of Cutaneous Melanoma: Analysis of a Case Series.J Clin Aesthet Dermatol. 2023 Dec;16(12):32-38. J Clin Aesthet Dermatol. 2023. PMID: 38125669 Free PMC article.
-
Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report.Case Rep Oncol. 2023 Nov 24;16(1):1451-1459. doi: 10.1159/000534475. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 38028569 Free PMC article.
-
Telehealth follow-up consultations for melanoma patients during the COVID-19 pandemic: Patient and clinician satisfaction.Cancer Med. 2023 Dec;12(23):21373-21388. doi: 10.1002/cam4.6679. Epub 2023 Nov 6. Cancer Med. 2023. PMID: 37930181 Free PMC article.
-
Evaluating the health and health economic impact of the COVID-19 pandemic on delayed cancer care in Belgium: A Markov model study protocol.PLoS One. 2023 Oct 30;18(10):e0288777. doi: 10.1371/journal.pone.0288777. eCollection 2023. PLoS One. 2023. PMID: 37903130 Free PMC article.
-
Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma.J Am Acad Dermatol. 2024 Feb;90(2):288-298. doi: 10.1016/j.jaad.2023.08.105. Epub 2023 Oct 4. J Am Acad Dermatol. 2024. PMID: 37797836
References
-
- Gershenwald JE, Scolyer RA, Hess KR, et al. ; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform . Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409 - DOI - PMC - PubMed
-
- Bhatia S, Tykodi SS, Lee SM, Thompson JA. Systemic therapy of metastatic melanoma: on the road to cure. Oncology (Williston Park). 2015;29(2):126-135. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical